Pfizer presenting on new developments at upcoming ASH meeting
The upcoming meeting of the American Society of Hematology (ASH) will feature several presentations of recent data from drug maker Pfizer regarding the company's growing portfolio in hematology compounds.
The compounds include:
Bosutinib against Imatinib in patients with chronic myeloid leukemia (CML), a two-year follow-up from the BELA trial.
Phase III results of an anti-CD22 drug, the investigational antibody drug conjugate Inotuzumab, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy.
PF-04449913,an investigational compound that inhibits Smoothened (SMO), a key component of the Hedgehog signaling pathway.
The anti-CD22 immunoconjugate gemtuzumab ozogamicin (Mylotarg) in combination with Rituxan followed by stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma
The 53rd annual meeting of the American Society of Hematology (ASH) will take place this year on December 10-13 in San Diego, California.
Source: MarketWatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
